Searching News Database: CAR T-cell
HSMN NewsFeed - 2 May 2024
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 9 Aug 2022
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
HSMN NewsFeed - 29 Jul 2022
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 17 Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 10 Apr 2019
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
HSMN NewsFeed - 28 Feb 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.